Across 34 randomized controlled trials, people who received stem-cell (mesenchymal stem cell, MSC) therapy were about 3× more likely to meaningfully improve blood-sugar control than placebo (odds ratio 2.79). Stem cell therapy helps regenerate insulin-producing beta cells, ease insulin resistance, and repair diabetic complications — for patients whose medication keeps climbing while neuropathy, nephropathy, or foot ulcers advance.

At Cell Grand Clinic in Osaka, Japan, that evidence is delivered under Japan’s MHLW-certified regenerative-medicine framework, using up to 200 million of your own (autologous) adipose-derived stem cells via IV — cultured about 7 weeks from your own minimal fat tissue. Never donor cells.

MHLW Type 2 certified. NIH-trained physician. 3,000+ stem cell cases. Diabetes Plan No. PB5250050.

Figures summarize published trials (see References). Individual results vary; stem cell therapy is not a guaranteed cure.

What Is Stem Cell Therapy for Diabetes?

Stem cell therapy for diabetes is a regenerative medicine approach that uses mesenchymal stem cells to regenerate insulin-producing beta cells, reverse insulin resistance, and repair diabetic complications including neuropathy, nephropathy, and retinopathy. A 2025 meta-analysis of 34 randomized controlled trials found that stem cell therapy is 2.79 times more effective than placebo at improving glycemic control (OR 2.79, 95% CI 1.63–4.75).

Stem cell therapy is not a fantasy—it’s a clinical reality refined across hundreds of peer-reviewed studies. And in Japan, it’s regulated, accessible, and increasingly proven for patients with type 1, type 2, and diabetic complications that conventional medicine cannot repair.

Why Conventional Therapy Hits a Wall

Insulin and oral medications control blood sugar but do not regenerate exhausted beta cells,
reverse insulin resistance, or repair the microvascular damage driving long-term complications.
More than 50% of long-term diabetes patients develop neuropathy, nephropathy, retinopathy, or
cardiovascular disease — outcomes that medication alone cannot prevent or reverse.

You take your medication, monitor your blood sugar, and follow every recommendation — and still the neuropathy spreads, the doses climb, and dialysis or laser treatment enters the conversation. Over 537 million people worldwide live with diabetes, and current strategies address the symptom (high blood sugar), not the underlying beta-cell loss, insulin resistance, and tissue damage that accumulate over years.

How Adipose-Derived Stem Cells Treat Diabetes

Adipose-derived stem cells (ADSCs) act through four mechanisms: they release growth factors
that protect and regenerate pancreatic beta cells, restore GLUT4 and IRS-1/AKT insulin signaling
pathways, suppress chronic inflammation via M1-to-M2 macrophage conversion, and improve
liver glucose metabolism. This systemic action targets the underlying disease, not only its
symptoms.

β-Cell Regeneration and Protection

Stem cells release growth factors — including VEGF, TGF-β, IGF-1, and HGF — that stimulate pancreatic β-cell regeneration and protect existing β-cells from further destruction. They reduce oxidative stress and suppress inflammatory cell death pathways.

For Type 1 Diabetes specifically, ADSCs modulate the misdirected autoimmune response that destroys β-cells — addressing the root immunological cause rather than compensating for its downstream effect. For Type 2 Diabetes, the focus shifts to regenerating β-cells exhausted by years of overdemand.

Reversal of Insulin Resistance at the Cellular Level

ADSC therapy increases GLUT4 expression — the glucose transporters in liver, muscle, and adipose tissue through which insulin moves glucose into cells. It restores the IRS-1/AKT signaling pathway, the primary molecular route through which insulin communicates with target tissues. It suppresses the NLRP3 inflammasome, a key inflammatory trigger that blocks insulin signaling.

This is not modest improvement in insulin sensitivity through a single pathway. This is restoration of the cellular machinery that makes insulin function properly — the same machinery that years of insulin resistance have progressively degraded.

Liver Function Restoration

The liver plays a central role in glucose regulation, and hepatic dysfunction is a significant contributor to both fasting and post-meal blood sugar elevation in diabetes. ADSC therapy improves liver function markers, reduces hepatic fat accumulation, and promotes glycogen synthesis — directly improving glucose metabolism through a route that oral medications cannot access.

Systemic Anti-Inflammatory Reset

Chronic low-grade inflammation is now recognized as a primary driver of both Type 1 and Type 2 Diabetes, not merely a consequence of them. ADSCs convert pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophages, expand regulatory T cells for sustained immune balance, and shift the systemic cytokine profile from destructive to protective.

No single pharmaceutical achieves this breadth of anti-inflammatory action. It is a system-wide reset — and it is the same mechanism through which ADSC therapy also addresses diabetic complications.

Type 1 vs Type 2 Diabetes Stem Cell Treatment: Which Responds Best?

Stem cell treatment works for both Type 1 and Type 2 diabetes through different mechanisms. In
Type 1, stem cells suppress the autoimmune attack destroying beta cells. In Type 2, they reverse
insulin resistance and regenerate exhausted beta cells.

Factor	Type 1 Diabetes	Type 2 Diabetes
Root cause	Autoimmune destruction of β-cells	Insulin resistance + β-cell exhaustion
Primary stem-cell action	Immune modulation — calming the autoimmune attack, protecting remaining β-cells	Metabolic restoration — easing insulin resistance, supporting exhausted β-cells
Clinical evidence	RCTs in newly-diagnosed patients: better HbA1c & C-peptide vs control; insulin production preserved (Hu 2013, n=29; ProTrans RCT 2023)	Stronger: HbA1c −1.31% in an n=91 double-blind RCT; −0.72 across 13 RCTs at 12 months
Best timing	Within 1–2 years of diagnosis (while β-cells remain)	Any stage — earlier tends to respond better
Complications treated	Neuropathy, nephropathy, retinopathy	Full range incl. foot ulcers, ED, cardiovascular

Beyond Blood Sugar: Treating Diabetic Complications with Stem Cells

Stem cell therapy directly targets the diabetic complications that drug therapy cannot address:
neuropathy, nephropathy, retinopathy, foot ulcers, erectile dysfunction, and cardiovascular
disease. By restoring microcirculation, regenerating nerves, and reducing inflammation, ADSC
therapy works on the underlying tissue damage — keeping limbs, vision, and kidney function that
conventional treatment can only slow.

Diabetic Neuropathy 

Neuropathic pain diminishes as stem cells regenerate nerve endings and restore blood flow. Many patients report improved sensation, warmth, and reduced numbness within 3–6 months.

Diabetic Nephropathy (Kidney Disease)

Kidney function stabilizes as stem cells reduce glomerular inflammation and promote podocyte repair. In a randomized trial (NEPHSTROM, 2023), MSC therapy slowed the rate of kidney-function (eGFR) decline versus placebo in type-2 patients with progressive diabetic kidney disease.

Diabetic Retinopathy

Vision and retinal health improve through restored retinal blood flow and reduced inflammation.

Diabetic Foot Ulcers

Enhanced wound healing through tissue regeneration and new blood vessel formation — directly addressing the condition that leads to amputation. Diabetic foot ulcers are the leading cause of non-traumatic lower limb amputation — this is the biological pathway that regenerative medicine is now demonstrating the ability to interrupt.

Erectile Dysfunction

Improved microcirculation and nerve function restores natural function — a result that PDE5 inhibitors (like Viagra) can only temporarily simulate. The mechanism and clinical evidence for this application are covered in depth in our article on stem cell therapy for erectile dysfunction.

Cardiovascular Complications

Improved endothelial function and reduced vascular inflammation — the most common cause of death in diabetic patients. Because the same vascular biology underlies arterial disease, stem cell therapy can also support reversing arterial plaque and treating atherosclerosis.

Stem Cell Therapy for Diabetes: Success Rate and Clinical Evidence

Stem cell therapy for diabetes shows a success rate roughly 3 times higher than placebo for improving glycemic control. The 2025 meta-analysis of 34 randomized controlled trials (Li et al., Stem Cell Research & Therapy) reported an odds ratio of 2.79 (95% CI 1.63–4.75) — patients receiving stem cell therapy were nearly 3 times more likely to achieve meaningful improvement. Independent 2025 reviews reach the same direction, including a government-commissioned systematic review of 20 RCTs (778 patients) and a 13-RCT meta-analysis showing lower HbA1c and insulin needs at 12 months.

Focus	Study type (size)	Key finding
Overall glycemic control	Meta-analysis (34 RCTs)	OR 2.79 — ~3× more likely to improve blood-sugar control (Li 2025)
Type 2 — double-blind RCT	RCT (n=91)	HbA1c −1.31%; 20% vs 4.55% reached target vs placebo (Zang 2022)
Type 2 — pooled RCTs	Meta-analysis (13 RCTs, 507 pts)	HbA1c −0.72 (P=0.0003); insulin −14.5 U/day at 12 months (2025)
Type 1 — newly diagnosed	RCT (n=29) + double-blind RCT	Better HbA1c & C-peptide vs control, sustained ~21 months; insulin production preserved (Hu 2013; ProTrans 2023)
Diabetic kidney disease	RCT (NEPHSTROM)	Slower eGFR decline vs placebo (2023)
Diabetic foot ulcers	Systematic review	~56% more likely to heal (RR 1.56)

Much of the strongest randomized evidence uses umbilical-cord / Wharton’s-jelly MSCs. These support the MSC approach broadly; Cell Grand Clinic uses autologous adipose-derived MSCs (your own cells). Individual results vary.

Type 2 Diabetes Stem Cell Therapy Success Rate

For type 2 diabetes, the evidence is the strongest. In a single-center, double-blind, placebo-controlled RCT of 91 adults, umbilical-cord MSC therapy lowered HbA1c by 1.31 percentage points (from ~9.0% to ~7.5%), and 20% of treated patients reached the combined target of HbA1c <7% plus a ≥50% insulin reduction, versus 4.55% on placebo (Zang et al., 2022). Pooling 13 RCTs, MSC therapy reduced HbA1c by 0.72 points and daily insulin by ~14.5 units at 12 months (2025 meta-analysis). Most type 2 patients see measurable HbA1c reduction within 3–6 months under physician supervision; results depend on disease duration and remaining β-cell function.

Type 1 Diabetes Stem Cell Therapy Success Rate

For type 1 diabetes, randomized evidence now goes beyond early pilots. In a randomized trial of 29 people with newly-diagnosed type 1 diabetes, Wharton’s-jelly MSC therapy produced significantly better HbA1c and C-peptide than standard insulin therapy alone, with benefits sustained over roughly 21 months (Hu et al., 2013). A later double-blind, placebo-controlled trial (ProTrans, 2023) found that allogeneic MSC treatment helped preserve the body’s own insulin production (C-peptide) in recent-onset patients. Separately, in 2025 an allogeneic stem-cell-derived islet therapy (zimislecel) enabled insulin independence in a phase 1–2 trial (NEJM) — a major advance, though it is a different modality (transplanted differentiated islet cells plus immunosuppression), not the IV autologous ADSC therapy described here.

The best window for type 1 is within 1–2 years of diagnosis, while functional β-cells remain. Stem cell therapy is not a guaranteed cure for type 1 diabetes.

Is Stem Cell Therapy Right for Your Diabetes?

You may benefit from stem cell therapy if you have Type 2 diabetes inadequately controlled by
medication, diabetic complications such as neuropathy or kidney disease, foot ulcers resistant to
standard care, or recently-diagnosed Type 1 diabetes (within 1–2 years). Active infection, current
cancer, and severe organ failure remain absolute contraindications.

Where Can You Get Stem Cell Treatment for Diabetes? Why Japan?

Stem cell treatment for diabetes is offered in Japan, Mexico, Thailand, Germany, and Panama — but regulatory rigor varies enormously. Japan is the only country with a dedicated national law, the Act on the Safety of Regenerative Medicine (2014), requiring government-registered protocols, MHLW-certified cell processing, and ongoing safety monitoring for every treatment. For international patients weighing where to be treated, that regulatory layer is the difference between a verifiable protocol and an unmonitored one.

Factor	🇯🇵 Japan	🇲🇽 Mexico	🇹🇭 Thailand	🇩🇪 Germany
Dedicated stem cell law	Yes (2014)	None	None	Partial
Government committee review	Mandatory	No	No	Varies
Licensed GMP cell-processing	Mandatory	Variable	Variable	Yes
National adverse-event registry	Mandatory	No	No	Partial

At Cell Grand Clinic (Osaka), every diabetes treatment runs under MHLW-certified Provision Plan No. PB5250050, using autologous (your own) adipose-derived stem cells — no donor cells, no rejection risk.

Why Cell Grand Clinic for Diabetes Stem Cell

Cell quality: Fresh, Pure, and Young.

Cells are expanded at a government-certified Cell Processing Center over approximately 7 weeks — a culture duration deliberately maintained to reach therapeutic concentrations of up to 200 million cells per session. Each batch is verified for viability (≥95%), purity via multi-marker surface antigen screening (CD73+, CD90+, CD105+; CD45–, CD34–), and low passage (P3) before administration. Low-passage cells retain full regenerative capacity; clinics that rush culture timelines or use high-passage cells deliver a biologically diminished product.

Cell Quality: The Key Factor That Impacts Stem Cell Therapy Outcomes Learn More

13 MHLW-certified treatments

The clinic holds government-certified Regenerative Medicine Provision Plans under Japan’s Act on the Safety of Regenerative Medicine for 13 distinct treatments — including the specific Type 2 plan for Diabetes Mellitus and Prediabetes (Plan No. PB5250050). This is not a general operating license; each individual treatment plan requires independent government committee review and approval.

Physician credentials

The Medical Director trained at the U.S. National Institutes of Health (NIH) in neurological disorders research and holds Diplomate status with the American Board of Regenerative Medicine (ABRM) — the primary international board certification in this specialty. Over 3,000 stem cell treatments have been performed, spanning osteoarthritis, diabetes, chronic pain, frailty, erectile dysfunction, hair loss, and aesthetic rejuvenation. Research achievements include first-author publication of the world’s first-in-human use of a PDE4B-specific PET tracer, conducted in collaboration with Pfizer Inc., and media coverage in The Wall Street Journal.

The Treatment Protocol for International Patients

Step 1 — Online Consultation: Remote screening, medical record review, personalized treatment planning.

Step 2 — Visit 1 (Fat Harvest): Tiny size fat harvest (~30 minutes, local anesthesia). Return to your hotel immediately.

On the very same day as your fat collection, you also have the option to receive exosome therapy. Culturing your own stem cells takes several weeks, and many patients don’t want to simply wait while their symptoms continue. Exosomes—the tiny signaling messengers naturally released by stem cells—can help calm inflammation and ease discomfort during this period, so you’re already starting to feel better by the time your cultured cells are ready. Think of it as a bridge: exosomes work with your treatment timeline, not against it.

Step 3 — Cell Culture (7 weeks): Expansion at our certified CPC. Return home during this period.

Step 4 — Visit 2 (Administration): IV drip ± local injection (60–90 minutes).

Total time in Japan: approximately 2–3 days per visit.

Innovative W-injection ~Our feature~

Systemic IV drip: 100–200 million ADSCs administered intravenously over 60–90 minutes. This is the primary route for Type 1 and Type 2 Diabetes, delivering cells systemically to address pancreatic function, insulin resistance, and vascular inflammation throughout the body.

Local injection: Customized dosing for targeted complications such as diabetic erectile dysfunction, where cavernosal injection achieves higher local cell concentration at the tissue level.

Combination protocol: IV drip plus local injection for patients with both systemic disease and specific complication targets.

Drug-Free ED Treatment: Stem Cells Without Pills or Implants Learn More Exosome Therapy: Same-Day, Cell-Free Regeneration Learn More

What to Expect: Timeline of Stem Cell Therapy Results

At 1–3 months: Initial improvements in glucose levels and neuropathy symptoms

At 3–6 months: Measurable HbA1c reduction and C-peptide increase

After 6months: Sustained effects and potential medication reduction under physician supervision.

Reverse Aging: How Stem Cell IV Therapy Actually Works Learn How Improving Atherosclerosis: Stem Cell Therapy for Vascular & Cardiac Health Learn More Knee Osteoarthritis: A Non-Surgical Path with Stem Cells Read Article Stem Cell Therapy in Japan: Plans, Pricing & What to Expect Read Guide

Frequently Asked Questions

Can stem cell therapy cure my diabetes?

We do not use the word “cure.” What clinical evidence demonstrates is that many patients achieve clinical remission — where blood sugar stabilizes to the point where medication can be significantly reduced or paused under physician supervision. The degree of improvement depends on your disease duration, remaining β-cell function, severity of insulin resistance, existing complications, and overall metabolic health.

Is autologous stem cell therapy safe?

Autologous ADMSC therapy has an excellent safety profile. Because we use your own cells, there is no immune rejection risk. A comprehensive 15-year meta-analysis published in Stem Cell Research & Therapy (2021) found no serious adverse events such as death and infection associated with MSC therapy. Japan’s regulatory framework adds an additional layer of safety assurance unmatched globally.

I am worried about complications like blindness or amputation. Can stem cell therapy help?

Yes. One of the most significant benefits of ADMSC therapy is angiogenesis — the formation of new blood vessels. By restoring microcirculation to the eyes, kidneys, nerves, and extremities, stem cell therapy directly opposes the vascular deterioration that leads to these devastating complications. This is something no oral medication can do.

Do you treat both Type 1 and Type 2 Diabetes?

Yes. For T1DM, ADMSCs halt autoimmune destruction and protect remaining β-cells. For T2DM, the focus is on reversing insulin resistance, reducing systemic inflammation, and regenerating β-cell function. Both types benefit substantially from treatment of diabetic complications.

Who is not a candidate for stem cell therapy?

Exclusion criteria are limited but important: active infection, recent or active cancer, severe organ failure, or inability to commit to follow-up monitoring. Most diabetic patients, including those with complications, are suitable candidates. A consultation determines individual eligibility.

Where can I get stem cell treatment for diabetes?

Stem cell treatment for diabetes is available in several countries, but regulatory quality varies significantly. Japan is currently the only country with a dedicated national law governing stem cell therapy — the Act on the Safety of Regenerative Medicine (2014) — which requires government registration, certified cell processing, and ongoing safety monitoring for every treatment. Cell Grand Clinic in Osaka, Japan holds MHLW-certified Regenerative Medicine Provision Plan No. PB5250050 specifically for diabetes and prediabetes. Other countries offering stem cell therapy for diabetes include Mexico, Thailand, Germany, and Panama — but none operate under an equivalent regulatory framework. When evaluating clinics, key questions to ask include: Is the treatment government-registered? Is the cell processing facility certified to GMP standards? Does the physician hold board certification in regenerative medicine?

How much does stem cell therapy for diabetes cost?

The cost of stem cell therapy for diabetes varies by country, clinic, and treatment protocol. In Japan, where treatments are government-regulated and use certified cell processing facilities, pricing reflects the quality control and regulatory compliance involved. At Cell Grand Clinic, treatment costs depend on the number of cells administered, the delivery method (IV drip, local injection, or combination), and whether complication-specific treatments are included. We recommend contacting us directly for a personalized cost estimate based on your medical history and treatment goals — WhatsApp and email inquiries are free of charge.

Can stem cell therapy reverse type 2 diabetes?

Clinical evidence suggests that stem cell therapy can partially reverse the metabolic dysfunction underlying type 2 diabetes — specifically insulin resistance and β-cell exhaustion — though the term “reversal” requires careful qualification. A 2025 meta-analysis found that stem cell (MSC) therapy improved glycemic control about 2.8 times more often than placebo overall (odds ratio 2.79), with more pronounced effects reported in type 2 diabetes. The mechanism involves restoration of GLUT4 glucose transporters, repair of insulin signaling pathways (IRS-1/AKT), and suppression of chronic inflammation (NLRP3 inflammasome). Many patients achieve significant HbA1c reduction and medication reduction under physician supervision. However, stem cell therapy is not a guaranteed cure — outcomes depend on disease duration, remaining pancreatic function, and adherence to metabolic management after treatment.

Is there a Japanese cure or remedy for diabetes?

Searches for a “Japanese cure for diabetes” usually refer to Japan’s regenerative-medicine approach — using stem cells to repair the underlying disease rather than only lowering blood sugar. Japan does not market a “cure.” Under the Act on the Safety of Regenerative Medicine (2014), clinics provide government-registered stem cell treatment that aims to regenerate β-cells, reduce insulin resistance, and repair complications. Many patients reach clinical remission — a significant, sustained reduction in medication — but outcomes vary and stem cell therapy is not a guaranteed cure.

Take Control: From Symptom Management to Regeneration

You have spent years managing your diabetes with medication. The numbers may look acceptable on paper. But if you are honest with yourself, you know the disease is progressing. The complications are advancing. The medication doses are increasing.

There is another path — one that does not replace your medications overnight, but offers something no pill or injection ever could: the opportunity to repair the damage, restore function, and potentially reduce your dependence on lifelong pharmaceutical management.

Stem cell therapy is not about abandoning conventional medicine. It is about adding a regenerative dimension to your treatment — one that works to heal the underlying disease rather than merely suppress its symptoms. This is the future of diabetes care, and it is available today under the strictest regulatory oversight in the world.

At Cell Grand Clinic in Osaka, Japan, we provide personalized stem cell therapy for international patients who are ready to move beyond management — toward regeneration.

📍 Shinsaibashi, Osaka, Japan  |  ✈️ 50 min from Kansai International Airport (KIX)

🌐 English consultations available  |  📋 MHLW Plan No. PB5250050 (Diabetes Mellitus and Prediabetes)

References

1. Li H, et al. A meta-analysis on application and prospect of cell therapy in the treatment of diabetes mellitus. Stem Cell Res Ther. 2025;16(1):249. PMID 40390031
2. Zang L, et al. Umbilical cord-derived MSCs in Chinese adults with type 2 diabetes: double-blind, randomized, placebo-controlled phase II trial. Stem Cell Res Ther. 2022. PMID 35505375
3. MSC-based therapy for type 1 & 2 diabetes: systematic review and meta-analysis of RCTs. Diabetol Metab Syndr. 2025. PMID 40462158
4. Efficacy and safety of stem cell therapy in diabetes mellitus — systematic review and meta-analysis (20 RCTs). Syst Rev. 2025. PMID 41639868
5. Hu J, et al. Long-term effects of Wharton’s jelly-derived MSCs for newly-onset type 1 diabetes (RCT, n=29). Endocr J. 2013. PMID 23154532
6. Carlsson PO, et al. Umbilical cord–derived MSCs preserve endogenous insulin production in type 1 diabetes: Phase I/II RCT (ProTrans). Diabetologia. 2023. PMID 37221247
7. Zimislecel (stem cell–derived islets) for type 1 diabetes. N Engl J Med. 2025. PMID 40544428
8. NEPHSTROM: MSC therapy in diabetic kidney disease, randomized trial. J Am Soc Nephrol. 2023. PMID 37560967
9. Elainein H, et al. ADSCs for diabetic foot ulcers: systematic review and meta-analysis. Diabetol Metab Syndr. 2025.
10. Wang Y, Yi H, Song Y. The safety of MSC therapy over the past 15 years: a meta-analysis. Stem Cell Res Ther. 2021;12:545. PMID 34663461

Disclaimer: Educational content, not medical advice. Individual results vary; outcomes depend on health condition, disease severity, and remaining β-cell function. Cell Grand Clinic operates under Japan’s Act on the Safety of Regenerative Medicine with required government authorizations.

Updated: 2026.07.10